Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05153239 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
A Phase 3 study of Relapsed Small Cell Lung Cancer, sponsored by PharmaMar.
- Active
- Registry status
- Phase 3
- Development phase
- 705
- Enrollment target
- 20
- Study locations
NCT05153239 is a Phase 3 study of Relapsed Small Cell Lung Cancer that is active but no longer recruiting, run by PharmaMar. The registered enrollment target is 705 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT05153239, a Phase 3 study of Relapsed Small Cell Lung Cancer, is active but no longer recruiting, sponsored by PharmaMar.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 705 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG Topotecan
- DRUG Lurbinectedin
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- Florida Cancer Specialists - North - St. Petersburg
- Florida Cancer Specialists - Panhandle - Tallahassee
- Florida Cancer Specialists - East - West Palm Beach
Nebraska
- Oncology Hematology West, PC (Grand Island) - Grand Island
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Omaha
Victoria
- BRICC - Ballarat Health Services - Ballarat Central
- Box Hill Hospital Eastern Health Clinical School - Box Hill
Other
- Northern Beaches Hospital - Frenchs Forest
- Gosford Hospital GH - Central Coast Cancer Centre - Gosford
Arizona
- Ironwood Cancer & Research Centers - Chandler
Arkansas
- Genesis Cancer and Blood - Hot Springs
Illinois
- Duly Health and Care - Joliet
Kentucky
- Norton Cancer Institue, Downtown - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2022-07-22 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05153239
The ClinicalTrials.gov registry entry for NCT05153239 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 705 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Irinotecan is the first listed.
NCT05153239 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Nebraska, Victoria.
Frequently Asked Questions
What is clinical trial NCT05153239 about?
NCT05153239 is a clinical study titled "Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)". Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topoteca...
What is the current status of trial NCT05153239?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 705 participants. The study started on 2022-07-22. Estimated completion is 2026-04.
What conditions does trial NCT05153239 study?
This clinical trial studies the following conditions: Relapsed Small Cell Lung Cancer.
What interventions are being tested in trial NCT05153239?
The interventions under investigation include: Irinotecan (DRUG), Topotecan (DRUG), Lurbinectedin (DRUG).
Who is sponsoring clinical trial NCT05153239?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05153239 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.